Last €3.63 EUR
Change Today +0.031 / 0.86%
Volume 266.7K
EVT On Other Exchanges
As of 1:55 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

evotec ag (EVT) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/5/13 - €5.18
52 Week Low
08/8/13 - €2.43
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EVOTEC AG (EVT)

Related News

No related news articles were found.

evotec ag (EVT) Related Businessweek News

No Related Businessweek News Found

evotec ag (EVT) Details

Evotec AG, together with its subsidiaries, provides drug discovery solutions for pharmaceutical and biotechnology companies, and academic institutions worldwide. Its services comprise target ID and validation, hit identification, compound management, chemistry, ADME (absorption, distribution, metabolism and excretion) profiling, proteomics, reagent production, in vitro pharmacology, in vivo pharmacology, and integrated services. The company has various products under clinical stage comprising DiaPep277 for diabetes type 1; EVT3021 for Alzheimer's disease; EVT201 for insomnia; Somatoprim for Acromegaly; EVT1032 for TRD; EVT401 inflammation; and ND³ for oncology. It also has various pre-clinical stage products, including ND³ for pain and oncology; endometriosis products; and EVT770 for diabetes type 2/1, as well as discovery stage products comprising EVT070 for diabetes type 2; and various products for inflammation, diabetes type 2, diabetes type 2/1, kidney disease, and Alzheimer’s disease. The company has alliances and partnerships with various companies comprising AstraZeneca AB, Bayer Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG, CHDI Foundation, Inc., MedImmune, LLC/AstraZeneca PLC, Genentech, Inc., the Jain Foundation, Janssen Pharmaceuticals, Inc., Johnson & Johnson Innovation, Ono Pharmaceutical Co., Ltd., UCB Pharma, and Fraunhofer Institute for Molecular Biology and Applied Ecology; and collaboration with Eternygen GmbH. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

645 Employees
Last Reported Date: 05/14/14
Founded in 1993

evotec ag (EVT) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: €601.0K
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €360.0K
Chief Operating Officer and Member of the Man...
Total Annual Compensation: €409.0K
Chief Scientific Officer and Member of the Ma...
Total Annual Compensation: €372.0K
Compensation as of Fiscal Year 2013.

evotec ag (EVT) Key Developments

Evotec to Collaborate with Fraunhofer in Joint Drug Discovery Programmes

Evotec AG announced an exclusive strategic collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organizations for internal and external drug discovery projects. This alliance expands Evotec's already powerful drug discovery platform with access to a broad range of complementary and highly innovative platforms and capabilities to progress own innovate projects and provides additional capabilities for customers and partners of Evotec and IME, respectively. The deal follows the joint decision of Evotec, Fraunhofer-Gesellschaft and the City of Hamburg to integrate the European ScreeningPort GmbH into the IME thereby forming the first Fraunhofer life science institution in the City of Hamburg.

Evotec AG Receives Payment as Part of its Discovery Alliance with Boehringer Ingelheim

Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a payment of EUR 1.0 million to Evotec. The payment was for the transition of a back-up compound from a respiratory programme into pre-clinical development. The completed research phase of this alliance has led to significant potential clinical milestones and royalties for compounds that are already in pre-clinical and clinical development if they progress successfully.

Evotec AG Appoints Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft as Auditor for the Year 2014

Evotec AG announced that at the annual general meeting held on June 17, 2014, the shareholders approved the appointment of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor for fiscal year 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVT:GR €3.63 EUR +0.031

EVT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $4.07 USD +0.01
CTI BioPharma Corp $2.69 USD -0.01
Exelixis Inc $3.33 USD +0.075
Galapagos NV €14.68 EUR +0.075
GlaxoSmithKline SAE £12.80 EGP 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation EVT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOTEC AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at